Erasca, Inc.
Erasca, Inc. (ERAS): 12 pipeline candidates · 1 upcoming catalyst · ~26 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
26.0 months
D/E 0.17 · 0% dilution
Lead: Phase 3
12 candidates
1 upcoming, next in ~2630d
0 buys · 3 sells (180d)
A transparent, data-derived signal for Erasca, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$4.3B
Cash
$47.7M
Quarterly Burn
$27.4M
Runway
26.0 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (12 candidates)
| Drug | Phase |
|---|---|
| ERAS-0015 | Phase 1 |
| ERAS-0015 in combination | Phase 3 |
| ERAS-007 | Phase 1 |
| ERAS-12 | Phase 1 |
| ERAS-3490 | Phase 1 |
| ERAS-4 | Phase 1 |
| ERAS-4001 | Phase 1 |
| ERAS-4001 in combination | Phase 3 |
| ERAS-601 | Phase 1 |
| ERAS-801 | Phase 1 |
Showing 10 of 12 candidates. Sign up for full pipeline.
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
219
Total value held
$2.96B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 22,499,476 | $364.0M |
| blackrock, inc. | 20,151,406 | $326.0M |
| rtw investments, lp | 16,157,175 | $261.4M |
| state street corp | 9,300,084 | $150.5M |
| janus henderson group plc | 7,421,932 | $120.0M |
| arch venture management, llc | 7,091,557 | $114.7M |
| geode capital management, llc | 5,996,149 | $97.0M |
| cormorant asset management, lp | 5,800,000 | $93.8M |
| woodline partners lp | 5,663,076 | $91.6M |
| affinity asset advisors, llc | 5,350,000 | $86.6M |
Showing top 10 of 219 institutional holders of Erasca, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Erasca, Inc.'s pipeline?
Erasca, Inc. (ERAS) has 12 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Erasca, Inc.'s lead drug candidate?
Erasca, Inc.'s most advanced tracked candidate is ERAS-0015 (Phase 1) for Metastatic Solid Tumors.
What is Erasca, Inc.'s next catalyst?
Erasca, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: MEKINIST" — expected August 30, 2033.
What is Erasca, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Erasca, Inc. has approximately 26.0 months of cash runway.
What is Erasca, Inc.'s market capitalization?
Erasca, Inc.'s market capitalization is approximately $4.3B.
Get the full picture on Erasca, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.